Speaker
Jingyi Luan, Ph.D.
Date
Location
University of Houston
Abstract
Fluorescent probes are the workhorse of fundamental and translational biomedical research and clinical diagnostics. However, low fluorescent signal-to-noise ratios and limitations in multiplexing capabilities remain persistent barriers to biomarker detection. The reliance on bulky readout instruments further limits their application in point-of-care settings.
In this presentation, I will highlight the development of nanoengineered fluorescent probes that achieve a 7,000-fold increase in brightness compared to conventional fluorophores, with minimal nonspecific binding. These advancements have enabled ultrasensitive sensing and imaging across various biomarkers, analytical platforms, and clinical sample types. Additionally, I will demonstrate the design of programmable DNA nanoprobes for highly multiplexed biomarker detection and their application in advancing biomarker discovery for neurological diseases. Finally, I will introduce cutting-edge nanotechnologies to measure disease biomarkers in dermal interstitial fluid, offering a minimally invasive alternative to traditional blood tests for point-of-care diagnostics.
In this presentation, I will highlight the development of nanoengineered fluorescent probes that achieve a 7,000-fold increase in brightness compared to conventional fluorophores, with minimal nonspecific binding. These advancements have enabled ultrasensitive sensing and imaging across various biomarkers, analytical platforms, and clinical sample types. Additionally, I will demonstrate the design of programmable DNA nanoprobes for highly multiplexed biomarker detection and their application in advancing biomarker discovery for neurological diseases. Finally, I will introduce cutting-edge nanotechnologies to measure disease biomarkers in dermal interstitial fluid, offering a minimally invasive alternative to traditional blood tests for point-of-care diagnostics.